Literature DB >> 3030486

Vascular responses to leukotriene B4, C4 and D4 following FPL 55712, indomethacin, saralasin, phentolamine and verapamil in the conscious rat.

J Filep, E Földes-Filep, J C Frölich.   

Abstract

The pressor and vascular permeability effects of leukotrienes B4 (LTB4), C4 and D4 were investigated in conscious unrestrained rats. Leukotrienes C4 and D4 (3.2-51 nmol kg-1 i.v.) caused an acute dose-dependent elevation of the mean arterial pressure, which was maximal after 2 min and returned to control levels within 14 min. Heart rate was significantly reduced by the higher doses of LTC4 and LTD4. LTB4 (up to a dose of 51 nmol kg-1) was essentially inactive. These effects of LTC4 and LTD4 were abolished by FPL 55712, a putative antagonist of sulphidopeptide leukotrienes and by verapamil, a calcium channel blocker. Indomethacin, phentolamine or saralasin pretreatment failed to modify the pressor response to LTC4 and LTD4. LTC4 and LTD4 furthermore caused an increase in haematocrit values, which was significantly attenuated by FPL 55712, indomethacin and verapamil. The present findings show that the pressor effect of LTC4 and LTD4 is not related to prostanoid release and can be reversed by calcium channel blockade; whereas the effect on vascular permeability seems to require the presence of both cyclo-oxygenase product(s) and calcium.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030486      PMCID: PMC1916953          DOI: 10.1111/j.1476-5381.1987.tb08973.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Bioconversion of C-6 sulfidopeptide leukotrienes by the responding guinea pig ileum determines the time course of its contraction.

Authors:  S Krilis; R A Lewis; E J Corey; K F Austen
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

2.  Effect of vasopressin on prostaglandin excretion in conscious dogs.

Authors:  G Fejes-Tóth; J Filep; V Mann
Journal:  J Physiol       Date:  1983-11       Impact factor: 5.182

3.  Cardiovascular responses to leukotriene C4 in the rat.

Authors:  V J Iacopino; T M Fitzpatrick; P W Ramwell; J C Rose; P A Kot
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

4.  Effect of calcium antagonists on leukotriene D4-induced contractions of the guinea-pig trachea and lung parenchyma.

Authors:  B M Weichman; R M Muccitelli; S S Tucker; M A Wasserman
Journal:  J Pharmacol Exp Ther       Date:  1983-05       Impact factor: 4.030

5.  Potent vasoconstriction of the isolated perfused rat kidney by leukotrienes C4 and D4.

Authors:  A Rosenthal; C R Pace-Asciak
Journal:  Can J Physiol Pharmacol       Date:  1983-04       Impact factor: 2.273

6.  Effects of intra-coronary administration of leukotriene D4 in the anaesthetized dog.

Authors:  L G Letts; D L Newman; S E Greenwald; P J Piper
Journal:  Prostaglandins       Date:  1983-10

Review 7.  Leukotrienes.

Authors:  S Hammarström
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

8.  Possible involvement of thromboxane in bronchoconstrictive and hypertensive effects of LTC4 and LTD4 in guinea pigs.

Authors:  A Ueno; K Tanaka; M Katori
Journal:  Prostaglandins       Date:  1982-06

9.  Selective inhibition of the lipoxygenase metabolic pathway of arachidonic acid by the SRS-A antagonist, FPL 55712.

Authors:  F B Casey; B J Appleby; D C Buck
Journal:  Prostaglandins       Date:  1983-01

10.  Differential effects of leukotrienes C4, D4 and E4 in the canine renal and mesenteric vascular beds.

Authors:  L P Feigen
Journal:  J Pharmacol Exp Ther       Date:  1983-06       Impact factor: 4.030

View more
  10 in total

1.  SK&F S-106203 inhibits leukotriene C4, leukotriene D4 and leukotriene E4 vasopressor responses in the conscious rat.

Authors:  E F Smith; M J Slivjak; J W Egan; R D Eckardt; J F Newton
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

2.  Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor.

Authors:  J G Filep; M G Sirois; A Rousseau; A Fournier; P Sirois
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

3.  Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice.

Authors:  M Ogata; T Matsumoto; M Kamochi; S I Yoshida; Y Mizuguchi; A Shigematsu
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat.

Authors:  J G Filep; E Földes-Filep; A Rousseau; P Sirois; A Fournier
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

5.  Modulation by nitric oxide of platelet-activating factor-induced albumin extravasation in the conscious rat.

Authors:  J G Filep; E Földes-Filep
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

6.  Pharmacological modulation of endothelin-induced contraction of guinea-pig isolated airways and thromboxane release.

Authors:  J G Filep; B Battistini; P Sirois
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

7.  Nitric oxide modulates vascular permeability in the rat coronary circulation.

Authors:  J G Filep; E Földes-Filep; P Sirois
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

8.  Enhancement by endothelin-1 of microvascular permeability via the activation of ETA receptors.

Authors:  J G Filep; M G Sirois; E Földes-Filep; A Rousseau; G E Plante; A Fournier; M Yano; P Sirois
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

9.  Endothelin-1-induced myocardial ischaemia and oedema in the rat: involvement of the ETA receptor, platelet-activating factor and thromboxane A2.

Authors:  J G Filep; A Fournier; E Földes-Filep
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

Review 10.  Cardiovascular effects of leukotrienes.

Authors:  J Fauler; J C Frölich
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.